MA52942A - Composés inhibiteurs d'oga - Google Patents

Composés inhibiteurs d'oga

Info

Publication number
MA52942A
MA52942A MA052942A MA52942A MA52942A MA 52942 A MA52942 A MA 52942A MA 052942 A MA052942 A MA 052942A MA 52942 A MA52942 A MA 52942A MA 52942 A MA52942 A MA 52942A
Authority
MA
Morocco
Prior art keywords
inhibitor compounds
oga inhibitor
oga
compounds
inhibitor
Prior art date
Application number
MA052942A
Other languages
English (en)
Inventor
José Manuel Bartolomé-Nebreda
Petrus Jacobus Johannes Antonius Buijnsters
Joseph Elisabeth Leenaerts
Lamenca Carolina Martinez
Daniel Oehlrich
Andrés Avelino Trabanco-Suárez
Gary John Tresadern
Roosbroeck Yves Emiel Maria Van
Adriana Ingrid Velter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA52942A publication Critical patent/MA52942A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA052942A 2018-06-21 2019-06-20 Composés inhibiteurs d'oga MA52942A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382456 2018-06-21

Publications (1)

Publication Number Publication Date
MA52942A true MA52942A (fr) 2021-04-28

Family

ID=62784079

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052942A MA52942A (fr) 2018-06-21 2019-06-20 Composés inhibiteurs d'oga

Country Status (8)

Country Link
US (1) US20210277003A1 (fr)
EP (1) EP3810586A1 (fr)
JP (1) JP2021528404A (fr)
CN (1) CN112313212B (fr)
AU (1) AU2019291101A1 (fr)
CA (1) CA3103049A1 (fr)
MA (1) MA52942A (fr)
WO (1) WO2019243535A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3048217A1 (fr) 2016-12-22 2018-06-28 Amgen Inc. Inhibiteurs de kras g12c et leurs procedes d'utilisation
ES2905676T3 (es) 2017-05-22 2022-04-11 Amgen Inc Inhibidores de KRAS G12C y métodos para su uso
CN111051306B (zh) 2017-09-08 2023-01-03 美国安进公司 Kras g12c的抑制剂及其使用方法
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (fr) 2018-06-12 2020-03-12 Amgen Inc. Inhibiteurs de kras g12c regroupant un cycle de piperazine et utilisation dans le traitement du cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
CA3117222A1 (fr) 2018-11-19 2020-05-28 Amgen Inc. Inhibiteurs de kras g12c et leurs procedes d'utilisation
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (fr) 2019-05-14 2020-11-18 Amgen, Inc Dosage d'inhibiteur de kras pour le traitement de cancers
CN114144414B (zh) 2019-05-21 2025-11-07 美国安进公司 固态形式
TW202132271A (zh) * 2019-11-14 2021-09-01 美商安進公司 Kras g12c抑制劑化合物之改善的合成
IL314883A (en) 2022-03-07 2024-10-01 Amgen Inc Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN114573467B (zh) * 2022-03-21 2023-11-21 北京印刷学院 2,4-二甲基-3-氨基苯甲酸的合成工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017003658B1 (pt) * 2014-08-28 2022-12-06 Asceneuron Sa Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica
US10913733B2 (en) * 2015-12-18 2021-02-09 Alectos Therapeutics Inc. Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof
EP3419976B1 (fr) * 2016-02-25 2021-04-07 Asceneuron SA Sels d'addition d'acide de dérivés de pipérazine
US11612599B2 (en) * 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors

Also Published As

Publication number Publication date
JP2021528404A (ja) 2021-10-21
CN112313212A (zh) 2021-02-02
WO2019243535A1 (fr) 2019-12-26
US20210277003A1 (en) 2021-09-09
EP3810586A1 (fr) 2021-04-28
CN112313212B (zh) 2023-05-05
CA3103049A1 (fr) 2019-12-26
AU2019291101A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MA52939A (fr) Composés inhibiteurs d'oga
MA47420A (fr) Composés inhibiteurs d'oga
IL292753A (en) Compounds
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
EP3941898C0 (fr) Composés fongicides
MA52948A (fr) Composés
IL286833A (en) Compositions containing brazzein
EP3740487A4 (fr) Composés benzamide
MA51669A (fr) Composés
DK4083038T3 (da) Pyridazinylthiazolcarboxamidforbindelse
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
MA53003A (fr) Composés
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA49006A (fr) Inhibiteurs d'ip6k
MA54521A (fr) Dérivés d'oxopyridine substitués
MA52946A (fr) Composés
EP3808747A4 (fr) Composé d'imidazopyridinone
EP4077318A4 (fr) Composés
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3833342A4 (fr) Composés d'imidazotétrazine
LT3867247T (lt) Naujieji junginiai
EP4003986A4 (fr) Composés inhibiteurs